EA201290627A1 - Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности - Google Patents

Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Info

Publication number
EA201290627A1
EA201290627A1 EA201290627A EA201290627A EA201290627A1 EA 201290627 A1 EA201290627 A1 EA 201290627A1 EA 201290627 A EA201290627 A EA 201290627A EA 201290627 A EA201290627 A EA 201290627A EA 201290627 A1 EA201290627 A1 EA 201290627A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kidney damage
compositions
methods
damage
prediction
Prior art date
Application number
EA201290627A
Other languages
English (en)
Inventor
Джозеф Андерберг
Джефф Грей
Пол Макферсон
Кевин Накамура
Джеймс Патрик Кампф
Original Assignee
Астьют Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астьют Медикал, Инк. filed Critical Астьют Медикал, Инк.
Publication of EA201290627A1 publication Critical patent/EA201290627A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/524—Thrombopoietin, i.e. C-MPL ligand
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для наблюдения за состоянием, диагностики, прогнозирования и определения схемы лечения субъектов, страдающих повреждением почек или предположительно имеющих повреждение почек. В частности, настоящее изобретение относится к применению одного или более анализов, позволяющих обнаружить маркер повреждения почек, выбранный из группы, состоящей из интерлейкина-5, бета-субъединицы рецептора интерлейкина-6, тканевого фактора, глобулина, связывающего половые гормоны, альфа-2-макроглобулина, аполипопротеина A-I, кальцитонина, тромбопоэтина, С-реактивного белка, молекулы межклеточной адгезии 3, металлоэластазы макрофагов, аполипопротеина В-100 и фибриногена, в качестве диагностических и прогностических биомаркеров повреждения почек.
EA201290627A 2010-02-05 2011-02-04 Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности EA201290627A1 (ru)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US30196110P 2010-02-05 2010-02-05
US30204510P 2010-02-05 2010-02-05
US30200910P 2010-02-05 2010-02-05
US30204710P 2010-02-05 2010-02-05
US30199210P 2010-02-05 2010-02-05
US30203910P 2010-02-05 2010-02-05
US30198110P 2010-02-05 2010-02-05
US30203210P 2010-02-05 2010-02-05
US30204810P 2010-02-05 2010-02-05
US30201210P 2010-02-05 2010-02-05
US30201610P 2010-02-05 2010-02-05
US30198510P 2010-02-05 2010-02-05
US30197010P 2010-02-05 2010-02-05
PCT/US2011/023832 WO2011097541A2 (en) 2010-02-05 2011-02-04 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
EA201290627A1 true EA201290627A1 (ru) 2013-05-30

Family

ID=44356097

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290627A EA201290627A1 (ru) 2010-02-05 2011-02-04 Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Country Status (11)

Country Link
US (1) US20130230871A1 (ru)
EP (1) EP2531622B1 (ru)
JP (2) JP5998055B2 (ru)
CN (1) CN102884205B (ru)
AU (1) AU2011213686B2 (ru)
CA (1) CA2788829A1 (ru)
EA (1) EA201290627A1 (ru)
HK (1) HK1174367A1 (ru)
MX (1) MX339765B (ru)
NZ (1) NZ601648A (ru)
WO (1) WO2011097541A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078736A2 (en) * 2010-12-09 2012-06-14 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
CA2944990A1 (en) 2014-04-09 2015-10-15 The Regents Of The University Of California Protein biomarkers for immune assessment and prediction of transplant rejection
JP2017530356A (ja) 2014-09-26 2017-10-12 ソマロジック, インコーポレイテッドSomaLogic, Inc. 心血管系のリスクイベントの予測及びその使用
EP3316159A4 (en) 2015-06-25 2019-08-14 Advanced Telecommunications Research Institute International PREDICTIVE EQUIPMENT BASED ON A SYSTEM ASSOCIATED WITH SEVERAL INSTITUTIONS AND PREDICTION PROGRAM
GB201511207D0 (en) * 2015-06-25 2015-08-12 Xvivo Perfusion Ab Isolated organ evaluation and treatment
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
CN109196119A (zh) * 2016-03-29 2019-01-11 株式会社国际电气通信基础技术研究所 用以预防或治疗选自由肾功能减退、慢性肾病和肾衰竭组成的组中的至少一种疾病的活性组分的候选物质的筛选方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
JPH02275359A (ja) * 1989-04-18 1990-11-09 Teijin Ltd 腎疾患の診断方法、診断試薬およびキット
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
DE69228682T2 (de) 1991-04-10 1999-07-01 Biosite Diagnostics Inc., San Diego, Calif. "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
WO1992018866A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
AU2006210794A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
WO2008084331A2 (en) * 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
ES2457243T3 (es) * 2006-09-08 2014-04-25 The Chancellor, Masters And Scholars Of The University Of Oxford Diagnóstico clínico de una fibrosis hepática utilizando APOL1 de suero humano como biomarcador
US8592170B2 (en) * 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease

Also Published As

Publication number Publication date
NZ601648A (en) 2015-05-29
EP2531622A4 (en) 2013-07-17
JP2016006430A (ja) 2016-01-14
JP6186400B2 (ja) 2017-08-23
JP2013519866A (ja) 2013-05-30
MX2012008955A (es) 2012-11-23
MX339765B (es) 2016-06-08
WO2011097541A2 (en) 2011-08-11
JP5998055B2 (ja) 2016-09-28
EP2531622A2 (en) 2012-12-12
CA2788829A1 (en) 2011-08-11
AU2011213686A1 (en) 2012-08-30
CN102884205B (zh) 2016-05-04
US20130230871A1 (en) 2013-09-05
WO2011097541A3 (en) 2011-11-10
EP2531622B1 (en) 2016-04-06
HK1174367A1 (zh) 2013-06-07
CN102884205A (zh) 2013-01-16
AU2011213686B2 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
EA201290627A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290387A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
van der Velde et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH
JP6126186B2 (ja) 腎損傷および腎不全の診断および予後のための方法および組成物
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2008060607A3 (en) Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2011004767A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
EA201291314A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290195A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
JP2013541706A5 (ru)
KR102431003B1 (ko) 신손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
EP2506016A2 (en) Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker
JP2022091846A (ja) Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
WO2012175672A3 (en) Diagnosis and/or prognosis of parkinson's disease dementia
RU2013138721A (ru) Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови
BR112015014232A2 (pt) lesão renal aguda
SI3171174T1 (en) Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease
US20160282344A1 (en) Methods and compositions for diagnosis and prognosis of sepsis
WO2012167887A8 (en) Diagnostic use of prosomatostatin